Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population studyResearch in context

• Váldodahkkit: María Eugenia Toledo-Romaní (Dahkki), Carmen Valenzuela-Silva (Dahkki), Minerva Montero-Díaz (Dahkki), Luisa Iñiguez-Rojas (Dahkki), Meiby Rodríguez-González (Dahkki), Mery Martínez-Cabrera (Dahkki), Rinaldo Puga-Gómez (Dahkki), Angel German-Almeida (Dahkki), Sonsire Fernández-Castillo (Dahkki), Yanet Climent-Ruiz (Dahkki), Darielys Santana-Mederos (Dahkki), Lissette López-González (Dahkki), Ileana Morales-Suárez (Dahkki), Delaram Doroud (Dahkki), Yury Valdés-Balbín (Dahkki), Dagmar García-Rivera (Dahkki), Patrick Van der Stuyft (Dahkki), Vicente Vérez-Bencomo (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2024-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Summary: Background: Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about the effectiveness of existing vaccines. The protection provided by the SOBERANA-02-Plus vaccination scheme against this variant has not yet been studied. We aimed to evaluate...